Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.

ABSTRACT:

Background

Chemotherapy is crucial for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and its survival benefits may outweigh adverse events. Oncotype DX (ODX) assesses this balance; however, it is expensive. Using nomograms to identify cases requiring ODX may be economically beneficial. We aimed to identify clinicopathological variables that correlated with the recurrence score (RS) and develop a nomogram that predicted the RS.

Methods

We included 457 patients with estrogen receptor-positive, HER2-negative breast cancer with metastases in fewer than four axillary lymph nodes who underwent surgery and ODX at our hospital between 2007 and 2023. We developed nomograms and internally validated them in 310 patients who underwent

SUBMITTER: Shibata A 

PROVIDER: S-EPMC11489311 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature